

1 Impact of Indolent Schistosomiasis on Morbidity and Mortality from
2 Respiratory Tract Infections in Preschool Age Children from a
3 Schistosomiasis Endemic Area.

4

5 Tariro L. Mduluz-Jokonya^{1,2}, Arthur Vengesai², Luxwell Jokonya^{3,2}, Amanda Thakataka⁴,
6 Herald Midzi², Takafira Mduluz^{1,2}, Elopy Sibanda⁵, Thajasvarie Naicker¹

7

8

9 ¹Optics & Imaging, Doris Duke Medical Research Institute, College of Health Sciences,
10 University of KwaZulu-Natal; Durban, KwaZulu-Natal, South Africa naickera@ukzn.ac.za

11 ²Department of Biochemistry, University of Zimbabwe, P.O. Box MP 167, Mt Pleasant,

12 Harare, Zimbabwe. mduluz@medic.uz.ac.zw ; tmduluz@yahoo.com

13 ³Department of Surgery, College of Health Sciences, University of Zimbabwe, P.O. Box MP
14 167, Mt Pleasant, Harare, Zimbabwe. doclux@gmail.com

15 ⁴Ministry of Health and Child Care, Gwanda District, Gwanda, Zimbabwe.

16 mandytaks@yahoo.com

17 ⁵Twin Palms Medical Centre, 113 Kwame Nkrumah Avenue, Harare, Zimbabwe

18 ensibanda@gmail.com

19

20 **Corresponding Author:**

21 Tariro L Mduluz-Jokonya

22 Email: tljokonya@gmail.com

23 **Abstract**

24 **Introduction:** Pneumonia is the biggest child killer, after the neonatal period. This is

25 especially so in children from developing countries who are exposed to other infections

26 simultaneously. In this article we investigated the impact of indolent *Schistosoma*

27 *haematobium* infection on background of a respiratory infection

28

29 **Method:** A cross sectional study with 237 preschool age children with a respiratory infection,

30 was performed during winter months in a schistosomiasis endemic area. Participants were

31 clinically examined and investigated appropriately. Upper respiratory tract infection (URTI)

32 and pneumonia were defined and classified as per IMCI and WHO guidelines, respectively.

33 *S. haematobium* infection diagnosis was by urine filtration on urine collected over three

34 consecutive days. Data was analysed using SPSS.

35

36 **Results:** *S haematobium* infection prevalence was 29% (69). Prevalence of respiratory
37 infections were as follows: common cold 79% (188), pneumonia 15% (36) and severe
38 pneumonia 6% (15). Eighty-one percent of participants with the common cold were *S.*
39 *haematobium* negative, whilst 80 % of those with severe pneumonia were infected.
40 Schistosomiasis infected children were at greater odds of developing; pneumonia (aOR=3.61
41 (95% CI 1.73-7.55) and severe pneumonia (aOR=21.13 (95% CI 4.65-95.89). High intensity
42 *S. haematobium* infection was associated with an increased risk of severe pneumonia RR=
43 23.78(95% CI 6.86-82.32). Mortality from coinfection emanated from severe pneumonia and
44 severe *S. haematobium* infection intensity (RR= 26.56 (95% CI 1.49 to 473.89). Number
45 needed to harm (NNH) for *S. haematobium* infected children who develop respiratory tract
46 infection was 4:1 for pneumonia and 5:1 for severe pneumonia.

47

48 **Conclusion:** The study demonstrated that coinfection with Schistosomiasis increases
49 morbidity and mortality from respiratory tract infections by up to 20 times in children less
50 than five years old. There is need to cover schistosomiasis screening and treatment in
51 children under 5 years old to avert mortality and morbidity due to coinfection with
52 respiratory infections.

53

54 **Key words:** respiratory tract infection, upper respiratory tract infection, pneumonia,
55 preschool age children, schistosomiasis, Under five mortality

56

57 **Background**

58 Pneumonia, an infection that inflames the respiratory system air sacs causing cough, fever
59 and difficulty to breath, was described over 2400 years ago by Hippocrates (1). Despite
60 modern day medicine, it is still the leading cause of death world-wide (2). It is the biggest

61 child killer, estimated to have 150.7 million new cases per year, of which 11- 20 million are
62 severe enough to require hospital admission (3). In Zimbabwe, pneumonia is the leading
63 cause of childhood deaths after the neonatal period (4).

64

65 Pneumonia frequently starts as an upper respiratory tract infection which progresses to the
66 lower respiratory tract (5). Micro-aspiration of contaminated secretions infects the lower
67 airways to cause pneumonia (6). Pneumonia is at times described as a bacterial infection of
68 the lung that require antimicrobial treatment (1). Though the pathogenic organism can be
69 viruses, fungi or parasites (7). Common implicated agents include: *streptococci pneumoniae*,
70 *Haemophilus influenzae*, *Chlamydophila pneumoniae*, rhinoviruses, coronaviruses, influenza
71 virus, parainfluenza virus, adenovirus and respiratory syncytial virus (5). About 45% of cases
72 in children are due to mixed infections of viruses and bacteria (8). A causative agent may not
73 be isolated in 50% of the cases despite careful testing (9). Ninety-five percent of clinical
74 cases in young children occur in developing countries (10). In developing countries, there are
75 endemic conditions that cause harm to the lungs. Damaged lungs are more susceptible to
76 pneumonia acquisition (11).

77

78 Schistosomiasis is common in Zimbabwe (12). It is caused by a trematode (worm) of the
79 genus *Schistosoma* (13). There are 24 species in the genus, seven can infest humans, in
80 Zimbabwe the two common species are *S. haematobium* and *S. mansoni*, with the former
81 having a higher prevalence (12,14 -18). *S. haematobium* is commonly associated with
82 genitourinary symptoms, however the infestation process affects other organs, such as the
83 lungs (13), especially during the worm developmental stages. Pulmonary schistosomiasis has
84 been described in two forms, acute pulmonary schistosomiasis (APS) and chronic pulmonary
85 schistosomiasis (CPS) (19, 20). APS is reported in naïve travelers who acquire

86 schistosomiasis and CPS being described as pulmonary hypertension common in the *S.*
87 *mansoni* species (21, 22).

88

89 Indolent in medical terminology refers to pathology causing little or no pain; inactive or
90 relatively benign (23). In most Preschool age children (PSAC) there is *S.haematobium*
91 infection with no visible signs, this is the indolent phase of schistosomiasis. As previously
92 reported, children are exposed *in utero*, and are again exposed postnatally (24). In most
93 PSAC, symptoms begin when children are of the school-going age (15) . The pulmonary
94 effect of *S. haematobium* infection has not been described in PSAC. Despite being the second
95 most common parasitic infection in the world, infecting about 50 million PSAC, the impact
96 of the coinfection of schistosomiasis and upper respiratory tract infections have not been
97 described, in endemic countries (25, 26). In this study we investigated the association
98 between *S. haematobium* infection and pneumonia in children presenting with symptoms of
99 respiratory tract infection under the age of five in a district in Zimbabwe.

100

101 **Methodology**

102 **Study site and design**

103 The study was a cross-sectional study, performed during winter months. It was carried out in
104 the Shamva district (31°40'0" E longitude and 17°10'0" S latitude) in Mashonaland Central
105 province, Zimbabwe (27). It lies 945 m above sea level, the climate is warm and
106 temperament with an average temperature of 20.2 °C and an annual rainfall of 887 mm.

107 Located in the Mazowe valley, Shamva district is an area with high farming activity due to
108 its fertile soil. Residents get their water supply from Mazowe river which spans through the
109 district and is a huge source of alluvial gold which the vast majority of population survives

110 through panning (27). Shamva District is a *S. haematobium* infection endemic area with the
111 highest prevalence of schistosomiasis in Zimbabwe at 62.3%, in PSAC schistosomiasis
112 prevalence was recorded to be 10% (28).

113

114 **Sample size**

115 Children aged five years and below with upper respiratory tract infection were recruited into
116 the study. Mothers were requested to bring their children to the clinic or to Expanded
117 Programme on Immunization (EPI) meeting points. The required sample size was calculated
118 to be 138 participants using the formula below with *S. haematobium* prevalence of the area
119 recorded as 10% (15):

$$n = \frac{z^2 pq}{e^2}$$

120 Where **z** is the z value for the 95% confidence interval, that is alpha = 5% ($z = 1.96$)

121 p = proportion/prevalence of the outcome to be investigated ($p = 0.10$)

122 $q = 1 - p = 0.90$

123 e = precision for the given confidence interval expected expressed as a decimal ($e = 0.05$)

124 $n = 138$

125 Using simple random sampling in the Shamva village, we recruited a total of 237 study
126 participants.

127

128 **Study inclusion criteria**

129 Children under five years old with signs and symptoms of an upper respiratory tract
130 infection were recruited into the study after exclusion of common non schistosomiasis co-

131 morbidities in the area which included malaria, tuberculosis, HIV infection, malnutrition,
132 asthma, allergies and family history of atopy.

133

134 **Ethical statement**

135 Ethical approval was obtained from Medical Research Council of Zimbabwe
136 (MRCZ/B/1854). Gatekeeper approval was obtained from the Provincial and District
137 Medical Directors and Community Leaders. Informed consent was obtained from the
138 parent/guardian of the children. All participants with confirmed disease were offered
139 treatment and parents/caregivers were counselled. Participants with severe pneumonia signs
140 were immediately transferred to the nearest health facility for further management.

141

142 **Clinical examination**

143 The clinical examination was conducted on PSAC (n = 237) by **two** medical practitioners
144 independent of each other at health facilities. Each clinician first took the history and then
145 examined each child according to the standard protocol (29,30) with special attention to the
146 respiratory system.

147

148 **Respiratory System Examination**

149 Inspection: Cyanosis of lips and nails, clubbing of fingers, respiratory rate, depth and
150 character of respiration, chest symmetry and expansion, use of accessory muscles, retractions
151 Palpation: Tenderness, subcutaneous crepitation, position of trachea, degree of chest
152 expansion (in cm with tape), tactile fremitus
153 Percussion: percussion notes (resonance, hyper-resonance, dull, flat), diaphragmatic
154 excursion

155 Auscultation: Character of breath sounds (vesicular, bronchovesicular, bronchial, tracheal),
156 crackles, wheezing, friction rub, vocal resonance

157

158 **Upper Respiratory Tract Infection (URTI) Diagnosis.**

159 URTI was diagnosed on clinical signs and symptoms after excluding allergy and influenza
160 according to IMCI guidelines. Signs and symptoms clinicians used to make a diagnosis
161 included sneezing, coughing, sore throat (reluctance to feed/unable to feed), nasal discharge
162 and nasal congestion (9,31–33).

163

164 **Pneumonia Diagnosis**

165 Pneumonia was defined as per WHO guidelines (7, 34).

166 Class 1: No pneumonia (cough/cold) - Normal respiratory rate, no use of accessory muscles
167 for breathing.

168 Class 2: Pneumonia - Tachypnoea: >50 breaths per minute(infants 2-11months),
169 >40 breaths per minute (children 12-59 months), No use of breathing accessory muscles.

170 Class 3: Severe pneumonia - Use of breathing accessory muscles with or without tachypnoea,
171 Any general danger signs: unable to drink, drowsiness, convulsions, reduced level of
172 consciousness, Oxygen saturation $SPO_2 < 90\%$, Stridor in a calm child.

173

174 ***S. haematobium* Infection Diagnosis**

175 Urine samples were collected by giving the caregiver an open- mouth urine container,
176 children 1 year and below used paediatric urine collectors attached by a clinician. The
177 samples were examined for macrohematuria using the Uristix reagent strips (Uripath,
178 Plasmatec, UK) dipped into fresh, well-mixed urine for 40 sec and the test area was
179 compared with a standard colour chart as per manufacturer's instructions. Approximately 50

180 ml of urine sample was collected from each participant on three consecutive days. The
181 samples were collected between 10am and 2pm, processed within two hours of collection by
182 the urine filtration method and were examined using microscopy for *S. haematobium* eggs
183 detection, as previously described (35). The number of eggs were reported per 10ml of urine.
184 The parasitology team recorded the results and the clinical team was blinded from them.

185

186 **Tuberculin Test for Tuberculosis**

187 About 0.1ml of liquid containing five tuberculin units purified protein derivative was injected
188 into the epidermis of the forearm. The result was read after 48hrs, an induration of >5mm
189 was read as positive and the child would be excluded from the study. Nonetheless, the
190 caregivers were referred to the nearest health care facility and the village health worker and
191 community nurse followed- up (31).

192

193 **Rapid Diagnostic Tests**

194 Rapid diagnostic tests were done for HIV infection and malaria with the caregiver's consent.
195 Children exposed to HIV were excluded from the study, and they received counselling on
196 the importance of having the child tested after weaning.

197

198 **Malnutrition Diagnosis**

199 Height and weight were measured with the participants in light/no clothing, an infantometer
200 baby board was used to measure height and for weight we used a baby scale. MUAC:
201 measurement was done on the left arm mid-point between the shoulder and the elbow tip,
202 with the arm relaxed and hanging down the body. Height and weight for age charts were used
203 to assess nutritional status. The caregivers were counseled concerning the correct nutritional

204 requirements and the importance of having a balanced diet. Children with malnutrition were
205 referred to the local health facility for further management.

206

207 **Statistical Methods**

208 Data analysis was performed using IBM SPSS Statistics version 23. Initial analysis was to
209 determine an association between participants with URTI advancing to pneumonia and *S.*
210 *haematobium* infection status. The statistical methods applied were the descriptive statistics,
211 bivariate and multivariate logistic regression modelling. The multivariate logistic regression
212 models were fitted to adjust for potential confounding factors for the five manifestations with
213 three explanatory variables, that is, sex, age and schistosomiasis infection. The effect of
214 different factors on the prevalence of schistosome infection and morbidity was determined
215 using logistic regression and the results reported as adjusted ORs (AORs) and 95% CI, along
216 with the test for significance, as previously described (36). Second analysis was to determine
217 the effects of different intensities of *S. haematobium* infection as a risk factor for developing
218 pneumonia or severe pneumonia. We calculated the population attributable fraction (PAF) of
219 the *S. haematobium* infected participants with different infection intensity having pneumonia
220 using the formula:

$$PAF = \frac{P_e(RR - 1)}{1 + P_e(RR - 1)}$$

221

222 Where P_e = Percentage of population exposed, RR=relative risk

223 Final analysis was to determine the impact to the population of *S. haematobium* infection as
224 a risk factor for pneumonia. For this we used the population attributable risk (PAR) of getting
225 pneumonia in the presence of *S. haematobium* infection calculated using the formula
226 (37,38):

$$PAR = \frac{P_0 - P_1}{P_0}$$

227 Where P_0 = participant with the condition divided by total participants

228 P_1 = number with condition unexposed divided by total participants unexposed

229

230 Number needed to harm (NNH) in the study population was calculated using the following

231 formula:

$$NNH = 1 / \text{incidence in exposed} - \text{incidence in unexposed}$$

232 *S. haematobium* infection was defined as the arithmetic mean egg count/10mL of at least two

233 urine samples collected on three consecutive days.

234 **Results**

235 **Demographics**

236 A total of 319 children under five years from 19 Shamva district villages were screened.

237 (Figure 1). Two hundred and thirty-seven preschool age children with signs and symptoms of

238 URTI were recruited into the study and followed up. The number of males was 129 (54%)

239 and females 108 (46%). The age was normally distributed with mean (SD) age of 3.2 (1.2). *S.*

240 *haematobium* prevalence was 29% (69) (Table 1). Amongst the study participant, 84% (201)

241 had exposure to contaminated water, whilst 15% reported no exposure to contaminated water.

242

243 **Relationship between *S. haematobium* Infection and Pneumonia**

244 After examination, 79% (182) of children had a simple cold or cough, 15% (36) had

245 pneumonia, 6.3 % (15) had severe pneumonia and 33% (5) of the severe pneumonia

246 participants deceased (Table 2). Eighty one percent of participants with the common cold

247 were *S. haematobium* negative, whilst 80 % of participants with severe pneumonia were *S.*
248 *haematobium* positive and 57% of *S. haematobium* positive had pneumonia.

249

250 The study participants after adjusting for sex and age, *S. haematobium* infection status and
251 indoor pollution, the infected children were at higher odds of presenting with the following:
252 pneumonia (aOR = 3.61 95 % CI 1.73-7.55) and severe pneumonia (aOR =21.13(4.65-95.89)
253 and mortality (aOR = 9.79 95% CI 3.82- 17.53). The risk of having pneumonia or severe
254 pneumonia in the *S. haematobium* infected individuals increased (Figure 2), with the
255 following relative risk (RR) noted: Pneumonia (RR=3.20(95% CI 1.78-5.75) and severe
256 pneumonia (RR=17.04 (3.98-73.01) with a mortality (RR = 26.56 (95% CI 1.49-473.80). The
257 PAF of pneumonia in schistosomiasis positive children was 31.61% and for severe
258 pneumonia was 82.38%. PAF due to respiratory tract and *S. haematobium* co-infection was
259 28%.

260 ***S. haematobium* Infection Intensity Association with Respiratory Infection**

261 Children with low intensity *S. haematobium* infection were at a higher risk of developing
262 pneumonia with RR=(2.62 (95% CI 1.13-6.08) (Figure 2). *S. haematobium* infected
263 participants with medium infection intensity were also more likely to present with pneumonia
264 (RR=4.31 (95% CI 1.45-12.81). High infection intensity was associated with a higher risk of
265 having severe pneumonia (RR=23.78 (95% CI 6.86-82.32). Having high intensity infection
266 had a RR=(12.22 (95% CI 1.86-80.10) of dying. In terms of population attributable fraction
267 in low *S. haematobium* infection intensity status attributed 26.79% of pneumonia, mild
268 infection mainly attributed to pneumonia PAF=16%. In high infection intensity had a high
269 PAF with severe pneumonia of 42% (Figure 3).

270

271 **Population Impact of *S. haematobium* Infection on Development of Pneumonia**

272 Population attributable risk percentages of schistosomiasis to pneumonia were as follows:

273 39.1% for pneumonia and 85.7% for severe pneumonia. Number needed to harm (NNH) by

274 not treating *S. haematobium* infection in the Shamva district was as follows:

275 1. For every **four** children exposed **one** will get pneumonia

276 2. For every **five** children exposed to *S. haematobium* infection **one** will get severe

277 pneumonia in the event of acquiring an upper respiratory tract infection.

278

279 **Discussion**

280 This study reveals that there is a strong association between having *S. haematobium* infection

281 and risk of pneumonia or severe pneumonia. In general, more than half of the severe disease

282 burden was attributable to *S. haematobium* infection. We also report an association between

283 high infection intensity status and development of severe pneumonia, whilst low and mild

284 infection intensity were more associated with URTI progression to pneumonia. Participants

285 who deceased all had severe pneumonia. Preschool age children with indolent

286 schistosomiasis who catch the common cold were at a higher risk of acquiring pneumonia or

287 severe pneumonia, according to our findings. This could be due to lung damage that occur

288 during *S. haematobium* infection predisposing the children to severe disease progression (20).

289 Pulmonary schistosomiasis occurs as early as the first exposure to infection, chest x-rays of

290 individuals with acute schistosomiasis have shown widespread non-specific infiltrates which

291 were accompanied by respiratory symptoms which include wheezes and dyspnea (39). These

292 respiratory signs and symptoms were reported to last for months after initial harm occurs

293 (19). Despite resolution of wheezes, the infected person is still exposed to further lung injury

294 during the chronic schistosomiasis phase (40–42).

295

296 This study shows that infection intensity was associated with URTI development turning into
297 the severe form of lower respiratory infection. Children with high intensity *S. haematobium*
298 infection had a significantly increased risk of severe pneumonia and death. This is in keeping
299 with previous reports on schistosomiasis and morbidity, which showed increased morbidity
300 with increased infection intensity (43–45). Schistosome eggs trapped in the host tissue are the
301 major cause of morbidity (46–48). In chronic schistosomiasis, eggs of the parasite are
302 released into the host human and are spread throughout the body and mainly into the lung
303 where they cause pulmonary arteritis (46). Infection intensity describes the parasitic load and
304 is measured as the number of eggs excreted, thus the higher the infection intensity the more
305 the associated morbidity.

306

307 To our knowledge, this is the first study to report a possible exacerbating effect of *S.*
308 *haematobium* infection on respiratory tract infection. We report *S. haematobium* infection to
309 have a significant population attributable fraction to severe pneumonia of 82.35% in our
310 study population. Furthermore, we found that for every four children with *S. haematobium*
311 infection who acquire an URTI, one will develop pneumonia. Whilst for every five *S.*
312 *haematobium* infected PSAC who acquire an URTI, one will develop severe pneumonia.
313 There have been reports of exacerbation of other clinical conditions with schistosomiasis, like
314 typhoid and malaria (49 – 52). To our knowledge, no reports have looked at the effect of
315 schistosomiasis on respiratory tract infections, particularly in PSAC.

316

317 Our study is of significant public health importance, notably in Zimbabwe there are about
318 1324 hospital admissions in PSAC due to pneumonia and severe pneumonia every month
319 (49). Despite strides in improving mortality by tackling malnutrition, HIV infection and the

320 introduction of polymer vaccines, the numbers still remain high. Thus, including routine
321 screening and early treatment of *S. haematobium* infection in a schistosomiasis endemic area
322 may have immense benefits in preventing severe pneumonia. There is need for policy makers
323 in endemic areas to further strengthen the drive to screen and treat schistosomiasis in PSAC
324 in a bid to decrease the mortality and morbidity associated with respiratory infections.
325 Furthermore, in the case of a respiratory pandemic, like SARS coronavirus-2, the impact on
326 children under five in schistosomiasis endemic area has the potential to be deadly.

327

328 Limitations to our study was the fact that it was carried out during a low schistosomiasis
329 transmission season, although it was a high URTI season. Our second limitation was that the
330 type of pathogen which caused the URTI could not be identified. Study strengths include the
331 fact that our sample size was more than the calculated size and the study was done in a high
332 schistosomiasis endemic zone, thus our results may be related to other endemic areas. This
333 study is of great importance in the public health sector, since respiratory tract infections are
334 the leading cause of children under-five years, mortality after the neonatal period.
335 Eliminating schistosomiasis could mean improving children under-five years mortality in
336 endemic areas.

337

338 **Conclusion**

339 This study demonstrates a harmful association between *S. haematobium* infection and
340 respiratory tract infections. *S. haematobium* infected children displayed a significantly
341 increased risk of developing pneumonia and severe pneumonia. Furthermore, the number
342 needed to harm in our study population was significantly high. This emphasizes the immense
343 benefit of early diagnosis and treatment of *S. haematobium* infection in PSAC, especially
344 during a global pandemic of a respiratory disease.

345 **Data Availability**

346 The statistical data on the parasitology and clinical scores used to support the findings of this
347 study are available from the corresponding author upon request.

348

349 **Conflict of Interest**

350 The authors declare that there is no conflict of interest.

351

352 **Funding Sources**

353 The study received funding from the TIBA. This research was commissioned by the National
354 Institute of Health Research (NIHR), Global Health Research Programme (16/136/33) using
355 UK aid from UK Government. The views expressed in this publication are those of the
356 authors and not necessarily those of the NIHR or the Department of Health and Social Care.

357

358 **Acknowledgements**

359 We would like to acknowledge the Ministry of Health and Child Care, the Medical Research
360 Council of Zimbabwe, village health workers, nursing staff, parents and children from
361 Shamva. A special thanks to members of the Biochemistry Department at the University of
362 Zimbabwe for technical support during field parasitology and sampling. Our most profound
363 gratitude to the participants and their parents or guardians for taking part in this study.

364

365 **Author Contributions**

366 TLMJ, LJ, TN, ES and TM conceived and designed the study. TLMJ, LJ, AT, AV, HM, ES
367 and TM performed the clinical examination or parasitology and the data analysis. TLMJ
368 wrote the first draft and all authors contributed to the manuscript and revised the final
369 version.

370 **References**

- 371 1. Tsoucalas G, Sgantzios M. General Medicine□: Open access Hippocrates , on the
372 Infection of the Lower Respiratory Tract among the General Population in Ancient
373 Greece. 2016;4(5).
- 374 2. Loubet P, Tubiana S, Claessens YE, Epelboin L, Ficko C, Bel J Le. Community-
375 acquired pneumonia in the emergency department□: an algorithm to facilitate
376 diagnosis and guide chest CT scan indication. 2019.
- 377 3. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.
378 Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions ,
379 1990 – 2010□: a systematic analysis for the Global Burden of Disease Study 2010.
380 2014;1990–2010.
- 381 4. Zimbabwe national statistics survey. Demographic and health surveys.
- 382 5. Drain PK. Acute Respiratory Diseases and Pneumonias. 2011.
- 383 6. Tang J, Chen J, He T, Jiang Z, Zhou J, Hu B, et al. Diversity of upper respiratory tract
384 infections and prevalence of Streptococcus pneumoniae colonization among patients
385 with fever and flu-like symptoms. 2019;1–10.
- 386 7. WHO. Revised WHO Classification and Treatment of Childhood Pneumonia at Health
387 Facilities: Evidence Summaries. World Health Organization. 2014; 26 p.

- 388 8. Report of a consultative meeting of children with pneumonia and HIV infection.
- 389 9. Short S, Bashir H, Marshall P, Miller N, Olmschenk D, Prigge K, Solyntjes L.
390 Diagnosis and Treatment of Respiratory Illness in Children and Adults. *Inst Clin Syst*
391 *Improv.* 2017; www.icsi.org
- 392 10. Rice, AL; Sacco, L; Hyder, A; Black R. Malnutrition as an underlying cause of
393 childhood deaths associated with infectious diseases in developing countries. *Bull*
394 *World Health Organ.* 2000;78(10):1207–21.
- 395 11. Macintyre CR, Chughtai AA, Zhang Y, Seale H, Yang P, Chen J, Yang P, Zhang D,
396 Wang Q. Viral and bacterial upper respiratory tract infection in hospital health care
397 workers over time and association with symptoms. 2017;1–9.
- 398 12. Midzi N, **Mduluza T**, Chimbari MJ, Tshuma C, Charimari L, Mhlanga G, Manangazira P,
399 Munyati SM, Phiri I, Mutambu SL, Midzi SS, Ncube A, Muranzi LP, Rusakaniko S,
400 Mutapi F (2014) Distribution of Schistosomiasis and Soil Transmitted Helminthiasis in
401 Zimbabwe: Towards a National Plan of Action for Control and Elimination. *PLoS Negl*
402 *Trop Dis* 8(8): e3014. doi:10.1371/journal.pntd.0003014.
- 403 13. Nelwan ML. Schistosomiasis: Life Cycle, Diagnosis, and Control. *Curr Ther Res -*
404 *Clin Exp* [Internet]. 2019;91(24):5–9. <https://doi.org/10.1016/j.curtheres.2019.06.001>
- 405 14. Osakunor DNM, Mduluza T, Midzi N, Chase-Topping M, Mutsaka-Makuvaza MJ,
406 Chimponda T. Dynamics of paediatric urogenital schistosome infection, morbidity and
407 treatment: A longitudinal study among preschool children in Zimbabwe. *BMJ Glob*
408 *Heal.* 2018;3(2):1–9.
- 409 15. Jenipher M, Makuvaza M, Zingoni ZM, Katsidzira A, Tshuma C, Chin'ombe N, Zhou

- 410 X, Webster B, Midzi N. Urogenital schistosomiasis and risk factors of infection in
411 mothers and preschool children in an endemic district in Zimbabwe. *Parasit Vectors*.
412 2019;1–15.
- 413 16. History T. Zimbabwe Control of Schistosomiasis. 2016;2015–6.
- 414 17. Taylor P, Makura O. Prevalence and distribution of schistosomiasis in Zimbabwe. *Ann*
415 *Trop Med Parasitol*. 1985;79(3):287–99.
- 416 18. **Mutsaka-Makuvaza MJ**, Matsena-Zingoni Z, Tshuma C, Ray S, Zhou XN, Webster
417 B, Midzi N. Reinfection of urogenital schistosomiasis in pre-school children in a
418 highly endemic district in Northern Zimbabwe: a 12 months compliance study.
419 *Infect Dis Poverty*. 2018;7(1):102. doi: 10.1186/s40249-018-0483-7. PMID: 30268157
- 420 19. Schwartz E. Pulmonary schistosomiasis. 2002;23:433–43.
- 421 20. Schaberg T, Rahn W, Racz P, Lode H. Pulmonary schistosomiasis resembling acute
422 pulmonary tuberculosis. *Eur Respir J*. 1991;4(8):1023–6.
- 423 21. Ross G A, Vickers D, Olds R G SSDPm. katayama syndrome. *lancet Infect Dis*.
424 2007;7(3):218–24.
- 425 22. Case A, Fever K, Schistosomiasis A. A Case of Katayama Fever (Acute
426 Schistosomiasis). *Med J Armed Forces India*. 2010;66(3):299.
- 427 23. Esserman LJ, Yau C, Thompson CK, Veer LJ Van, Borowsky AD, Hoadley KA,
428 Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS. Use of
429 Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow
430 Risk Over 2 Decades. 2017;3(11):1503–10.
- 431
432 24. Freer JB, Bourke CD, Durhuus GH, Kjetland EF, Prendergast AJ. Review

- 433 Schistosomiasis in the first 1000 days. *Lancet Infect Dis*. 2018;18(6):e193–203.
434 [http://dx.doi.org/10.1016/S1473-3099\(17\)30490-5](http://dx.doi.org/10.1016/S1473-3099(17)30490-5)
- 435 25. World Health Organization. Schistosomiasis Key facts. World Heal Organ. 2018;1–5.
436 <https://www.who.int/en/news-room/fact-sheets/detail/schistosomiasis>
- 437 26. WHO. schistosomiasis. *Global Health Estimates 2015: Deaths by Cause, Age, Sex, by*
438 *Country and by Region, 2000-2015*. 2016.
439 http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html%0AG
440 *eneva*, World Health Organization; 2016.
- 441 27. Zimbabwe National Statistic Agency. Provincial report: Mashonaland Central.
442 Zimbabwe Popul Census. 2012;
- 443 28. Osakunor DNM, Mduluza T, Midzi N, Chase-Topping M, Mutsaka-Makuvaza MJ,
444 Chimponda T, Eyoh E, Mduluza T, Pfavayi LT, Wami WM, Amanfo SA, Murray J,
445 Tshuma C, Woolhouse MEJ, Mutapi F. Dynamics of paediatric urogenital schistosome
446 infection, morbidity and treatment: a longitudinal study among preschool children in
447 Zimbabwe. *BMJ Glob Health*. 2018 ;3(2):e000661. doi: 10.1136/bmjgh-2017-000661.
448 PMID: 29616147
- 449 29. Carter J, Müller-Stöver I, Östensen H. *Good clinical diagnostic practice A guide for*
450 *clinicians in developing countries to the clinical diagnosis of disease and to making*
451 *proper use of clinical diagnostic services*. 2005.
- 452 30. University of Glasgow. *MB ChB Clinical History and Examination Manual*. 2015;
- 453 31. Child TTHE. *IMCI chart Booklet*. 2002;1–39.
- 454 32. Tantilipikorn P, Auewarakul P. Airway allergy and viral infection. *Asian Pacific J*
455 *Allergy Immunol*. 2011;29(2):113–9.

- 456 33. Center for Disease Control and Prevention. Nonspecific Upper Respiratory Tract
457 Infection. Cent Dis Control Prev. 2006;134(6):2001.
- 458 34. World Health Organization. Recommendations for management of common childhood
459 conditions. Parassitologia. 2012;84. <http://europepmc.org/abstract/MED/10697870>
- 460 35. Mott, K., Baltes, R., Bambagha J. and Baldassini B. Field studies for detection of a
461 reusable polyamide filter for detection of *Schistosoma haematobium* eggs by urine
462 filtration. ropenmedizin Parasitol 1982;33227-228. 1982;(33):227–8.
- 463 36. Wami WM, Nausch N, Bauer K, Midzi N, Gwisai R, Simmonds P, Mduluzza T,
464 Woolhouse M, Mutapi F. Comparing parasitological vs serological determination of
465 *Schistosoma haematobium* infection prevalence in preschool and primary school-aged
466 children: Implications for control programmes. Parasitology. 2014;141(14):1962–70.
- 467 37. Risk A, Risk PA. Appendix III-B. :155–62.
- 468 38. Risk PA. Definition of PAR PAR = Population Attributable Risk. 2014;8–11.
- 469 39. Lambertucci JR. Acute schistosomiasis mansoni: Revisited and reconsidered. Mem
470 Inst Oswaldo Cruz. 2010;105(4):422–35.
- 471 40. Town C, Africa S, Saade A, Carton E, Damotte D, Yera H. Lung Involvement in
472 Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma.
473 2018;24(86949):2375–8.
- 474 41. King CH, Galvani AP. Underestimation of the global burden of schistosomiasis.
475 Lancet. 2018;391(10118):307–8. [http://dx.doi.org/10.1016/S0140-6736\(18\)30098-9](http://dx.doi.org/10.1016/S0140-6736(18)30098-9)
- 476 42. Kolosionek E, Graham BB, Tuder RM, Butrous G. Pulmonary vascular disease
477 associated with parasitic infection — the role of schistosomiasis. Clin Microbiol
478 Infect. 2010;17(1):15–24.: <http://dx.doi.org/10.1111/j.1469-0691.2010.03308.x>

- 479 43. Mazigo HD, Kirway L, Ambrose EA. Prevalence and intensity of *Schistosoma*
480 *mansoni* infection in pediatric populations on antiretroviral therapy in north-western
481 Tanzania: A cross-sectional study. *BMJ Open*. 2019;9(7):1–6.
- 482 44. Mott KE, Dixon H, Osei-Tutu E, England EC. Relation between Intensity of
483 *Schistosoma haematobium* Infection and Clinical Haematuria and Proteinuria. *Lancet*.
484 1983;321(8332):1005–8.: [https://doi.org/10.1016/S0140-6736\(83\)92641-7](https://doi.org/10.1016/S0140-6736(83)92641-7)
- 485 45. Chipeta M, Ngwira B, Kazembe L. Analysis of Schistosomiasis *haematobium*
486 Infection Prevalence and Intensity in Chikhwawa, Malawi: An Application of a Two
487 Part Model. *PLoS Negl Trop Dis*. 2013;7:e2131.
- 488 46. Lucia C, Silva M. Endothelial Cells as Targets of the Intravascular Parasitic Disease
489 Schistosomiasis a. *Vascular Responses to Pathogens*. Elsevier Inc.; 2016. 195–207 p.:
490 <http://dx.doi.org/10.1016/B978-0-12-801078-5/00015-7>
- 491 47. Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: An update. *Curr Opin*
492 *Infect Dis*. 2004;17(5):439–47.
- 493 48. Weerakoon KGAD, Gobert GN, Cai P, Mcmanus P. Advances in the Diagnosis of
494 Human Schistosomiasis. 2015;28(4):939–67.
- 495 49. Dondo V, Mujuru H, Nathoo K, Jacha V, Tapfumanei O, Chirisa P, Manangazira P,
496 Macharaga J, de Gouveia L, Mwenda JM, Katsande R, Weldegebriel G, Pondo T,
497 Matanock A, Lessa. Pneumococcal Conjugate Vaccine Impact on Meningitis and
498 Pneumonia Among Children Aged < 5 Years - Zimbabwe , 2010 – 2016.
499 2019;69:2010–6.
- 500
501
502

503 **Figure Legends**

504

505 Figure 1: Profile showing the inclusion and excluded of the children and the final participants
506 included in the study.

507

508 Figure 2: Relative risk ratio of *S. haematobium* infection intensity measured by eggs in 10mls
509 of urine and pneumonia diagnosed by clinical examination.

510

511 Figure 3: *S. haematobium* infection intensity and population attributable fraction

512

513

514

515

516 Table 1: Characteristics of the Study Participants

517

| Characteristic | | Total (N=237) |
|------------------------------------|-----|---------------|
| Age mean (SD) | | 3.2 (1.2) |
| Gender | | |
| Males | | 54% (129) |
| Females | | 46% (108) |
| Pneumonia class among participants | | |
| No pneumonia (Common cold) | | 182 (77%) |
| Pneumonia | | 37(16%) |
| Severe pneumonia | | 16(7%) |
| Risk Factors | | |
| Exposure to contaminated water | No | 15% (36) |
| | Yes | 84% (201) |
| Indoor pollution | No | 5.5%(13) |
| | Yes | 94.5%(224) |

518

519

520

521

522

523

524

525 Table 2: Relationship between *S. haematobium* Infection and Pneumonia

| | | No Pneumonia (common cold) N=182 | Pneumonia N=37 | Severe pneumonia N=16 | Mortalities N=5 |
|---|----------|--|-------------------------|-----------------------------|---|
| <i>S. haematobium</i> Infection status | negative | 81% (148) | 43%(16) | 12% (2) | 0 |
| | positive | 19% (34) | 57%(21) | 88%(14) | 5 |
| Total prevalence % (n) | | 79%(182) | 15% (37) | 7% (16) | 2% (5) |
| adjusted odds ratio (95% CI) | | 0.16(0.08-0.33)* | 4.16(2.01-8.59)* | 21.13(4.65-95.89)* | 9.79(3.82- 17.53)*^a |
| Relative risk (95% CI) | | 0.26(0.16-0.43)* | 3.20(1.78-5.75)* | 17.04(3.98-73.01)* | 26.56(1.49-473.80)*^a |
| Population attributable fraction | | - | 31.61% | 82.38% | 27.88% |
| Mortality | | 0% | 0% | 31%(5) | |

526 * significant at 5% level of significance($p < 0.05$, ^a in relation to severe pneumonia

527

Figure 1




Figure 2




Figure 3

